Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Pseudo Biologist who wrote (530)	1/23/2000 12:52:00 AM
From: Larry Liebman	Respond to of 52153

I stand corrected. I assume the additional MLNM shares went to pay for LKST. Actually, that LKST deal at $35/sh looks pretty good right now! I wonder if the tech model of dominant "gorilla's" will be played out in this sector. Who would have believed that the abysmal climate for bio's, and the absence of IPO's and seed money, would support such a powerful rally?!!

To: Pseudo Biologist who wrote (530)	1/23/2000 9:11:00 AM
From: biowa	Read Replies (4) \| Respond to of 52153

PB, Tossing out a random thought that will probably get lost in the rally: At what point does the sum total of future revenue streams (admittedly 5-10 years out in some cases) implied by combined biotech, pharma, med device and other med technology market caps exceed a reasonable expectation for US or even global health spending? Depressed pharma prices in 1999 may have provided some room, but... Not that anyone cares about revenues right now, but I thought I'd book mark it for later. biowa